Search

Your search keyword '"Giménez-Argente C"' showing total 3 results
Start Over Author "Giménez-Argente C"
3 results on '"Giménez-Argente C"'

1. Efecto de la suplementación con vitamina D en los efectos secundarios musculoesqueléticos relacionados con los inhibidores de la aromatasa para el cáncer de mama: cohorte B-ABLE

Author

Pineda-Moncusí M, Servitja S, Extebarria Foronda I, García-Vives E, Cos ML, Giménez-Argente C, Rodríguez-Morera J, Rial A, García-Giralt N, Xavier Nogues X1, and Ovejero D

Subjects
inhibidores de la aromatasa, vitamina d, cáncer de mama, pérdida ósea, artralgia, Medicine, Osteopathy, RZ301-397.5
Abstract

Objetivo: Evaluar el efecto de la suplementación con vitamina D en las complicaciones musculoesqueléticas relacionadas con el tratamiento con inhibidores de la aromatasa (IA) en pacientes con cáncer de mama. Material y métodos: Estudio observacional prospectivo de mujeres en tratamiento con IA, reclutadas en la cohorte B-ABLE. Las pacientes con niveles séricos iniciales de 25(OH)D (25-hidroxivitamina D) 0 a los 3 meses, mediante regresión logística. Resultados: La suplementación con vitamina D al inicio del tratamiento con IA disminuyó el riesgo tanto de artralgia incidente como de su empeoramiento. El umbral efectivo de 25(OH)D en suero para reducir el dolor articular se estableció en 40 ng/ml. Sin embargo, este umbral no se relacionó significativamente con los cambios óseos al año de seguimiento. No obstante, los niveles de vitamina D se correlacionaron inversamente con la pérdida ósea de la columna lumbar (CL) (β=0,177% [IC 95%: 0,014 a 0,340]). Conclusiones: La administración de suplementos de vitamina D con el objetivo de alcanzar niveles séricos de 25OHD de al menos 40 ng/ml es protectora para la artralgia. Los niveles de vitamina D a los tres meses podrían predecir el riesgo de pérdida ósea en CL al año de tratamiento con IA. Por lo tanto, se recomiendan dosis altas de vitamina D en estas pacientes, que son más propensas a sufrir afecciones musculoesqueléticas.

Published
2021
Full Text
View/download PDF

2. Effect of vitamin D supplementation on aromatase inhibitor-related musculoskeletal side effects for breast cancer: B-ABLE cohort

Author

Pineda-Moncusí, M, Servitja, S, Extebarria Foronda, I, García-Vives, E, Cos, ML, Giménez-Argente, C, Rodríguez-Morera, J, Rial, A, García-Giralt, N, Xavier Nogues, X, and Ovejero, D

Abstract

Objective: To assess the effect of vitamin D supplementation on musculoskeletal complications related to aromatase inhibitor (AI) treatment in patients with breast cancer. Material and methods: Prospective observational study of women undergoing AI treatment, recruited in the B‐ABLE cohort. Patients with baseline serum 25 (OH) D (25‐hydroxyvitamin D) levels 0 at 3 months, was evaluated using logistic regression. Results: Vitamin D supplementation at the start of AI treatment decreased the risk of both incident arthralgia and its worsening. The effective threshold of 25 (OH) D in serum to reduce joint pain was established at 40 ng/ml. However, this threshold was not significantly related to bone changes at one year of follow‐up. However, vitamin D levels were in‐ versely correlated with lumbar spine bone loss (LS) (β=0.177% [95% CI: 0.014 to 0.340]). Conclusions: Vitamin D supplementation aimed at achieving serum 25(OH)D levels of at least 40 ng/ml is protective for arthralgia. Vitamin D levels at three months could predict the risk of bone loss in LS at one year of AI treatment. The‐ refore, high doses of vitamin D are recommended in these patients, who are more prone to musculoskeletal conditions.

Published
2021

3. Evidence of functional declining and global comorbidity measured at baseline proved to be the strongest predictors for long-term death in elderly community residents aged 85 years: a 5-year follow-up evaluation, the OCTABAIX study

Author

Formiga F, Ferrer A, Padros G, Montero A, Gimenez-Argente C, and Corbella X

Subjects
oldest old, mortality, co-morbidity, instrumental activity of daily living, Geriatrics, RC952-954.6
Abstract

Francesc Formiga,1,2 Assumpta Ferrer,3 Gloria Padros,4 Abelardo Montero,1,2 Carme Gimenez-Argente,1 Xavier Corbella1,2,5 On behalf of the Octabaix study members 1Internal Medicine Department, Geriatric Unit, Hospital Universitari de Bellvitge, Institut Català de la Salut, 2Bellvitge Biomedical Research Institute, IDIBELL, L’Hospitalet de Llobregat, 3Primary Care Centre “El Plà”, Direcció d’Atenció Primària Costa de Ponent, Institut Català de la Salut, Sant Feliu de Llobregat, 4South Metropolitan Clinical Laboratory, Direcció d’Atenció Primària Costa de Ponent, Institut Català de la Salut, L’Hospitalet de Llobregat, 5Albert J Jovell Institute of Public Health and Patients, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain Objective: To investigate the predictive value of functional impairment, chronic conditions, and laboratory biomarkers of aging for predicting 5-year mortality in the elderly aged 85 years.Methods: Predictive value for mortality of different geriatric assessments carried out during the OCTABAIX study was evaluated after 5 years of follow-up in 328 subjects aged 85 years. Measurements included assessment of functional status comorbidity, along with laboratory tests on vitamin D, cholesterol, CD4/CD8 ratio, hemoglobin, and serum thyrotropin.Results: Overall, the mortality rate after 5 years of follow-up was 42.07%. Bivariate analysis showed that patients who survived were predominantly female (P=0.02), and they showed a significantly better baseline functional status for both basic (P

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results